Patients must have had =< prior cytotoxic regimen for metastatic disease (unless enrolling in the Progressive Brain Metastases Cohort); note that endocrine and immunotherapies do not count as cytotoxic regimens With the exception of steroid pretreatment or the administration of intrathecal cytarabine, patients must not have received any prior cytotoxic chemotherapy for either the current diagnosis of B-ALL or any cancer diagnosed prior to the initiation of protocol therapy on AALL; patients cannot have secondary B-ALL that developed after treatment of a prior malignancy with cytotoxic chemotherapy; patients receiving prior steroid therapy may be eligible for AALL Cytotoxic therapy: at least days since the completion of cytotoxic therapy with the exception of hydroxyurea, which is permitted up to hours prior to the start of protocol therapy, or maintenance chemotherapy, or intrathecal chemotherapy (methotrexate strongly preferred) administered at the time of the required diagnostic lumbar puncture to establish baseline CNS status Patients who have received treatment with any other cytotoxic chemotherapy prior to beginning protocol therapy (other than allowed in above criteria) are excluded Patients who have received any prior cytotoxic chemotherapy for the current diagnosis of ALCL or any cancer diagnosed previously are not eligible ALL developing after a previous cancer treated with cytotoxic chemotherapy Patients who have received any prior cytotoxic chemotherapy or biologics for sex cord-stromal tumors (SCSTs) Subjects who have received any cytotoxic chemotherapy within the last days prior to biopsy Patients with AML must be unlikely to benefit from cytotoxic chemotherapy defined by any one of the following criteria: Must not have received cytotoxic chemotherapy within days of entry on to this study Cytotoxic chemotherapy - weeks Patients must be willing to forego other cytotoxic and non-cytotoxic therapies against the tumor while being treated on this protocol Patients who have received prior cytotoxic, non-cytotoxic or experimental drug therapies for brain tumor are excluded Cytotoxic chemotherapy or immunotherapy within weeks of study entry Prior cytotoxic chemotherapy is allowed. Any cytotoxic chemotherapy within days prior to initiation of study drug. Prior cytotoxic chemotherapy and/or radiation therapy within weeks of treatment Patients must not have received more than prior lines of cytotoxic chemotherapy for advanced disease; treatment with targeted agents or biologic agents such as antibodies as single agents will not count as a line of cytotoxic chemotherapy received cytotoxic chemotherapy for either metastatic HSPC or CRPC within the last weeks or other investigational agents within weeks >= weeks off cytotoxic chemotherapy Received any other investigational agent or systemic cytotoxic chemotherapy within the preceding weeks Chemotherapy: at least weeks since prior cytotoxic chemotherapy Conventional cytotoxic chemotherapy: ? weeks Patients must be willing to forego other cytotoxic and non-cytotoxic therapies against the tumor while being treated on this protocol Patients who have received prior cytotoxic, non-cytotoxic or experimental drug therapies for brain tumor are excluded In the absence of rapidly proliferative disease, the interval from prior treatment to time of initiation will be at least days for cytotoxic or non-cytotoxic (immunotherapy) agents. Patients cannot be on a targeted agent (e.g., sunitinib or everolimus) or receiving cytotoxic chemotherapy (e.g., capecitabine or temozolomide); they cant be on telotristat ethyl; previous use is acceptable if the patient has been off for over one month Treatment with cytotoxic chemotherapy within months prior to enrollment Patients currently on cytotoxic chemotherapy or immunotherapy are eligible, not including anti-VEGF therapy Has received cytotoxic chemotherapy for post-transplant relapse prior to study entry Any prior myeloma-directed therapy including cytotoxic chemotherapy, biologic therapy, or radiotherapy within weeks of enrollment The subject has received cytotoxic chemotherapy, molecular targeted therapy, or immunotherapy within days before the first dose of study drug (trametinib) A weeks interval from any investigational agents or cytotoxic chemotherapy to start of study is required Prior therapy requirements:\r\n* Wt-GIST: previously untreated participants are eligible\r\n* PHEO/PGL with germline SDH subunit mutation: I-methyl-iodobenzylguanine (MIBG) in patients with MIBG avid tumors or cytotoxic chemotherapy (cyclophosphamide, vincristine, and dacarbazine [CVD] or temozolomide) is required prior to enrollment on this trial; however, patients who have refused cytotoxic chemotherapy or for whom treatment on this protocol prior to receiving cytotoxic chemotherapy is felt to be in the best interest for the patient by the local investigator will also be eligible\r\n* HLRCC-associated renal cell cancer: previously untreated participants are eligible Last dose of any systemic non-taxane cytotoxic chemotherapy completed at least one day prior to Day . Last dose of any systemic taxane cytotoxic chemotherapy completed at least weeks prior to Day Subjects receiving cytotoxic chemotherapy Be at least days from last administration of cytotoxic chemotherapy or other investigational agent Prior cytotoxic chemotherapy or radiotherapy for this lymphoma PHASE ONLY: Patient participants previously untreated for AML who are considered unfit for cytotoxic chemotherapy by virtue of performance status, comorbidities, advanced age and/or low likelihood of response based on disease characteristics, or who decline cytotoxic induction chemotherapy Patients must have been previously treated, as defined by treatment with at least one prior cytotoxic chemotherapy regimen or agent; patients may have received any number of prior cytotoxic agents Prior systemic chemotherapy or radiation therapy for urothelial carcinoma or cytotoxic chemotherapy for another malignancy within year of study entry are ineligible Patients must be >= days from previous cytotoxic treatment Cytotoxic chemotherapy within days prior to enrollment Chemotherapy: cytotoxic (At least days since last dose of chemotherapy prior to first dose of tazemetostat) Chemotherapy: non-cytotoxic (e.g., small molecule inhibitor) (At least days since last dose of non-cytotoxic chemotherapy prior to first dose of tazemetostat) At the time of registration, patient must be at least weeks from other prior cytotoxic chemotherapy No intention to use cytotoxic chemotherapy within the next months Treatment with cytotoxic chemotherapy within previous days, or failure to recover from adverse events (AEs) due to cytotoxic chemotherapy administered more than days previous (however, ongoing neuropathy is permitted) Prior cytotoxic chemotherapy or molecularly-targeted agents (e.g. erlotinib, crizotinib), unless > years prior Ongoing treatment with cytotoxic therapy Patients with active cytotoxic chemotherapy or radiation therapy are excluded Cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) within weeks before the first dose of study treatment Prior cytotoxic chemotherapy or biologic therapy for the treatment of CRPC; Note: sipulecel-T is permitted with a -week washout Subjects who have any previous treatment with DNA-damaging cytotoxic chemotherapy (prior taxane chemotherapy allowed). Has been treated with more than two lines of cytotoxic chemotherapy or molecular targeted therapy or interferon for Lung NET Must not have received cytotoxic chemotherapy within days of entry on to this study Has had prior systemic cancer cytotoxic chemotherapy within the past four weeks at the time of the start of the lymphodepletion regimen Prior treatment with cytotoxic chemotherapy for advanced NSCLC weeks from cytotoxic agents week from non-cytotoxic agents Patients must be willing to forego other cytotoxic and non-cytotoxic drug or radiation therapy against the tumor while enrolled in the study. Last cytotoxic chemotherapy or more days or biologic therapy treatment or more days before study start (greater than or equal to days if nitrosourea was administered) Eligible subjects must have completed appropriate treatment for their primary disease and be off cytotoxic chemotherapy and any immunosuppressive agents such as systemic steroids for at least days prior to enrollment; patients should continue trastuzumab monotherapy throughout the course of this protocol; concurrent hormonal and biphosphonate therapies are allowed No prior cytotoxic chemotherapy for metastatic disease; prior immunotherapy is permitted Patients treated with prior chemotherapy, cytotoxic chemotherapy, radiation, biotherapy, or any investigational agent > days prior to lymph node removal are eligible weeks from prior cytotoxic therapy Prior treatment with any cytotoxic chemotherapy in metastatic setting; prior treatment with cytotoxic chemotherapy is allowed only if used in neoadjuvant, adjuvant or for bladder preserving protocols, as long as was administered > months prior to starting study Patients may not be on any cytotoxic chemotherapy or hormonal treatment for breast cancer during protocol treatment; (trastuzumab is allowed in HER positive patients) Cytotoxic therapy: at least days since the completion of cytotoxic therapy with the exception of hydroxyurea, low dose cytarabine, and intrathecal chemotherapy which is permitted up to hours prior to the start of protocol therapy; for patients with aggressive disease that is in the peripheral blood and rising, this day washout period may be omitted Prior cytotoxic chemotherapy or radiotherapy for this lymphoma Cytotoxic chemotherapy, steroids or monoclonal antibody (Mab) within weeks of enrollment, except anti-Tac Mab (i.e. daclizumab) which cannot be used within weeks of enrollment; hydroxyurea is considered different from cytotoxic chemotherapy and may be used up to the day before enrollment providing it is not increased during the week prior to enrollment and that the patients disease burden is not decreasing during that time Concurrent treatment with any cytotoxic therapy Chemotherapy: cytotoxic (At least days since last dose of chemotherapy prior to first dose of tazemetostat) Chemotherapy: non-cytotoxic (e.g., small molecule inhibitor) (At least days since last dose of non-cytotoxic chemotherapy prior to first dose of tazemetostat) No more than total previous regimens of systemic therapy, including cytokines and cytotoxic chemotherapy. Cytotoxic chemotherapy within days before randomization Cancer for which intraperitoneal cytotoxic chemotherapy is planned Eligible for cytotoxic chemotherapy Chemotherapy: cytotoxic At least days Prior cytotoxic chemotherapy; No prior cytotoxic chemotherapy to treat their metastatic disease Cytotoxic chemotherapy within weeks of first trilaciclib (GT) dose Cytotoxic chemotherapy; at least days since last dose Any prior cytotoxic chemotherapy regimen, including antibody drug conjugates for RCC or cytotoxic chemotherapy within weeks of study treatment for OCCC Prior treatment with greater than (>) cytotoxic chemotherapy regimen for metastatic breast cancer Systemic cytotoxic chemotherapy, antineoplastic biologic therapy, or major surgery within weeks of the first dose of study medication Prior cytotoxic chemotherapy for metastatic prostate cancer. Prior cytotoxic chemotherapy with curative intent in the neoadjuvant or adjuvant setting is allowed but must have been completed at least months prior to registration. No cytotoxic chemotherapy is allowed during protocol specified therapy. Age > or equal to years; patients younger than who are unsuitable for or unwilling to receive standard cytotoxic chemotherapy are also eligible to be enrolled Investigation or cytotoxic therapy within days or nitrosoureas within days of the first treatment with G- Up to prior cytotoxic regimens for advanced or metastatic breast cancer patients with no prior cytotoxic regimens for advanced or metastatic disease will only be allowed if they relapsed during or within months of (neo-) adjuvant cytotoxic therapy that included a taxane and/or anthracycline, if not contraindicated. Systemic cytotoxic chemotherapy, antineoplastic biologic therapy, or major surgery within days of the first dose of trial medication Less than days from the completion of any previous cytotoxic chemotherapy (with the exception of hydroxyurea) Cytotoxic chemotherapy within the days prior to randomization Subject has received prior cytotoxic chemotherapy or chemoradiotherapy for NSCLC. Patients who have received no more than prior cytotoxic treatment regimen. No cytotoxic chemotherapy within weeks of starting study treatment Prior cytotoxic chemotherapy for the treatment of CRPC, including taxanes, mitoxantrone and estramustine Subject with rapidly progressing visceral disease who has not received and is thought to be able to tolerate cytotoxic chemotherapy. (However, subject who has previously received cytotoxic chemotherapy is permitted). Patients must be at least days post cytotoxic chemotherapy prior to enrollment At least days from the completion of any previous cytotoxic chemotherapy or biological therapy at time of initiation of POL. Having recovered from prior surgery, radiation, chemotherapy (cytotoxic and noncytotoxic) to toxicity grade =< or returned to baseline; previous treatment with immunotherapies, cytotoxic drugs, or other targeted agents is permitted; if cytotoxic chemotherapy was previously received, the last dose must be >= month before leukapheresis; for other agents, the last dose must be >= days before leukapheresis Prior use of cetuximab or another epidermal growth factor receptor (EGFR) inhibitor is allowable and if used as a single agent should not be considered as a cytotoxic chemotherapy (nor should other targeted therapies be considered as a prior line of cytotoxic chemotherapy) Previous cytotoxic chemotherapy for advanced (metastatic) disease Patient has received an investigational agent or cytotoxic chemotherapy (excluding hydroxyurea) within weeks of study Subjects should have received no anti-leukemic therapy (except hydroxyurea) prior to the first dose of crenolanib as follows: for days for classical cytotoxic agents and for five times the t/ (half-life) for FLT inhibitors and antineoplastic agents that are neither cytotoxic nor FLT inhibitors (e.g. hypomethylating agent or MEK inhibitor) All previous cytotoxic chemotherapy, monoclonal antibody therapy, immune therapy should be washed out weeks before apheresis and must be completed at least weeks prior to pre-infusion lymphodepletive chemotherapy. Prior bevacizumab and any cytotoxic chemotherapy More than prior lines of cytotoxic chemotherapy Cytotoxic chemotherapy: ? duration of the most recent cycle of the previous regimen (a minimum of weeks for all) Planned cytotoxic chemotherapy during the SRS or WBRT No prior treatment with cytotoxic chemotherapy No cytotoxic chemotherapy within days prior to registration for protocol therapy. Most recent cytotoxic chemotherapy, immunotherapy, chemo-immunotherapy, or investigational agents < days from the date of randomisation or half-lives of the agent, whichever is longer. Most recent non-cytotoxic targeted therapy < days from the date of randomisation. Systemic cytotoxic therapy within weeks of treatment Prior cytotoxic or cyclosporin treatment for HLH. Patients with prior cytotoxic chemotherapy are eligible to participate if they have been progression free for at least months since the initiation of cytotoxic chemotherapy Candidates for cytotoxic chemotherapy A drug provided as maintenance therapy following cytotoxic chemotherapy will be considered to be part of that regimen. Anyone with a second malignancy expected to require cytotoxic chemotherapy or immune modulating therapy within months of enrollment weeks from prior cytotoxic therapy Any prior cytotoxic chemotherapy except Temozolomide Patients must have had prior cytotoxic therapy for their disease; patients with diffuse large B-cell lymphoma must have been treated with at least prior cytotoxic therapies Patients must have received at least line of cytotoxic chemotherapy Patients may have had up to two prior cytotoxic chemotherapy regimens for their disease (immunological or targeted therapy e.g. vaccine, IL-, B-RAF inhibitors, will not be considered prior cytotoxic chemotherapy). Patient should not have been treated with Docetaxel, Paclitaxel or other taxanes. More than prior cytotoxic chemotherapy regimen for advanced disease Patient has had prior cytotoxic chemotherapy for the treatment of metastatic melanoma; however, patients who are randomized to the physicians choice arm and treated with cytotoxic chemotherapy as part of this study will be allowed to cross over to receive their assigned molecularly guided therapy should disease progression occur and they meet the specific eligibility requirements of the molecularly guided agent Positive cytotoxic crossmatch Anyone with a second malignancy expected to require cytotoxic chemotherapy or immune modulating therapy within months of enrollment Patient has received more than one line of cytotoxic chemotherapy Subject must have had at least one prior cytotoxic chemotherapy regimen for unresectable or metastatic disease. Prior taxane therapy is allowed. Concurrent anti-cancer cytotoxic chemotherapy Use of cytotoxic chemotherapy within days of registration Prior cytotoxic chemotherapy or biologic therapy for CRPC Prior treatment with more than one line of cytotoxic chemotherapy; prior treatment with one line of cytotoxic chemotherapy is permitted; prior treatment with targeted therapy (such as ipilimumab, anti-programmed cell death [PD] and BRAF inhibitor) is permitted At least days from last cytotoxic chemotherapy Scheduled to start a new chemotherapy regimen (any line, combination cytotoxic chemotherapy with targeted agents are allowed) Treatment with cytotoxic chemotherapy within weeks prior to registration Patient has received an investigational agent or cytotoxic chemotherapy (excluding hydroxyurea) within days of study entry Received cytotoxic chemotherapy within days (or days for nitrosureas or mitomycin C) prior to the first scheduled dose of MEDI. Cytotoxic chemotherapy within weeks. days from administration of prior cytotoxic therapy with the following exceptions: About to begin either oral or cytotoxic chemotherapy Eligible patients must not be currently undergoing standard cytotoxic chemotherapy Individuals who are actively undergoing standard cytotoxic chemotherapy month years following completion of cytotoxic chemotherapy treatment for any cancer, and are experiencing neuropathy Planned cytotoxic chemotherapy during the WBRT only; patients may have had prior chemotherapy Treatment with cytotoxic chemotherapy within the preceding four weeks Patients who have not had any cytotoxic chemotherapy within days of beginning the study Currently on or expected to start cytotoxic chemotherapy within week of study enrollment Participants who have received cytotoxic chemotherapy within year prior to screening breast MRI Other cytotoxic agents: weeks Subjects must have received cytotoxic chemotherapy within months of consent date (measured from the start date of chemotherapy). All previous cytotoxic chemotherapy, monoclonal antibody therapy, or immune therapy must be washed out weeks before apheresis and must be completed at least weeks prior to pre-infusion lymphodepletive chemotherapy. Other cytotoxic agents: weeks Cytotoxic chemotherapy within weeks prior to study enrollment Previous cytotoxic therapies, including cytotoxic investigational agents, for multiple myeloma within defined values prior to start of study treatment